27/09/2021at 14:25

EQT wants to stay in WS Audiology for "several years"

The capital fund EQT has no intentions of selling its shares in WS Audiology for the time being.

BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

The Swedish private equity firm EQT isn't planning on selling its investment in WS Audiology (WSA) any time soon.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

GN rejects notion of selling Hearing division, again
For subscribers
WS Audiology still chewing over listing of online hearing company
For subscribers
CEO at WSA: No clarity on EQT exit plans yet
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Michael Løvbjerg, CEO and co-founder of Lizn | Foto: Lizn / Pr

Hearing health

New hearing company 14 years in the making – "We expect to rise to the top"

Three hearing aid industry veterans have in secret founded a company, Lizn, while refining over many years a hearing device that is now ready to be launched.

For subscribers

Regulation

Another UK authority looking into Novo Nordisk's marketing violation

For subscribers

Pharma & biotech

Ascendis Pharma initiates long-term study of Skytrofa

For subscribers

Pharma & biotech

Roche and Eli Lilly to collaborate on early Alzheimer's detection test

For subscribers

Britt Meelby Jensen, CEO of Ambu | Foto: Ambu/pr

Medtech

Ambu CEO: Technology, scalability and partnerships will ensure growth

For subscribers

Medtech

Nordea finds new Ambu targets encouraging and trustworthy

New hearing company 14 years in the making – "We expect to rise to the top"

Three hearing aid industry veterans have in secret founded a company, Lizn, while refining over many years a hearing device that is now ready to be launched.

For subscribers

Regulation

Another UK authority looking into Novo Nordisk's marketing violation

The Medicines and Healthcare products Regulatory Agency will investigate ”whether regulatory action is also appropriate” after another UK authority took action against the Danish drugmaker.

For subscribers

Medtech

Nordea finds new Ambu targets encouraging and trustworthy

Having looked over the Danish medtech company’s pipeline, the bank sees ”an opportunity for a strong double-digit earnings growth in the medium to long term.”